Parallel Fluidics Raises $7M to Advance Microfluidic Technology for IVF and Life Sciences

Parallel Fluidics, a company pioneering on-demand microfluidic manufacturing solutions with applications in IVF and other life sciences, has raised $7 million in seed funding. The round was led by J2 Ventures with support from 8VC and Praxis.

The company’s technology is gaining momentum in the fertility sector, where it’s being used by Overture Life, a startup focused on streamlining IVF procedures. Overture Life has integrated Parallel Fluidics’ latest MV-2 microvalve into their next-gen IVF systems, allowing for enhanced flow control.

“Precision fluid control and the efficient handling of biological samples are critical in advanced fertility treatments like IVF,” explained Lionel Matthys, Chief Product Officer at Overture Life. “Parallel Fluidics’ microfluidic systems address these needs, providing faster and more reliable processes that can improve patient outcomes and push reproductive medicine forward.”

The global microfluidics market, valued at $32 billion, is projected to reach $117.13 billion by 2031. Microfluidic technology allows scientific testing to occur on a microscopic scale, enabling higher precision, speed, and throughput in life sciences.

Jon Bronson, PhD, Managing Partner and co-founder of J2 Ventures, highlighted the value Parallel Fluidics brings to R&D in the life sciences. “Scientists and engineers developing the next breakthroughs shouldn’t have to reinvent core microfluidic systems,” he said. “Parallel Fluidics’ on-demand manufacturing services offer production-ready devices within days, which accelerates the journey from concept to market and minimizes development risks. This is transformative for time-sensitive, cost-efficient R&D.”

With the new funding, Parallel Fluidics will expand its on-demand design and manufacturing platform, as well as its hardware and software solutions. The MV-2 microvalve, which enables products to function at the point of care in settings like doctor’s offices and clinics, is also set for commercialization.

“As more life science products integrate microfluidics, scientific teams often face challenges unrelated to their innovations, such as flow control and automation,” said Josh Gomes, CEO and co-founder of Parallel Fluidics. “Our mission is to help these teams create scalable, reliable products that accelerate disease detection and improve medicine. With this funding, we’ll grow our manufacturing services, broaden our hardware options, and develop new design and analytics software to power the future of life science tools.”